AMY H. CANDIDO, State Bar No. 237829 1 (acandido@wsgr.com) 2 CATHERINE R. LACEY, State Bar No. 291591 (clacey@wsgr.com) 3 WILSON SONSINI GOODRICH & ROSATI, P.C. One Market Plaza Spear Tower, Suite 3300 Telephone: (415) 947-2000 5 Facsimile: (415) 947-2009 6 Attorneys for Plaintiff Carrum Health, Inc. 7 8 UNITED STATES DISTRICT COURT 9 NORTHERN DISTRICT OF CALIFORNIA 10 Carrum Health, Inc., 11 CASE NO.: 12 Plaintiff, **COMPLAINT FOR** DECLARATORY JUDGMENT OF 13 v. NON-INFRINGEMENT OF U.S. PATENT NOS. 9,123,072; 11,030,665; 14 MDsave Shared Services, Inc. and MDsave, Inc., 11,244,370; 11,315,160; AND 15 11,341,556 Defendants. 16 **DEMAND FOR JURY TRIAL** 17 18 19 20 21 22 23 24 25 26 27 28



Plaintiff Carrum Health, Inc. ("Carrum") hereby seeks a declaratory judgment of non-infringement of United States Patent Nos. 9,123,072; 11,030,665; 11,244,370; 11,315,160; and 11,341,556 as follows:

NATURE OF THE ACTION

- 1. This is an action for a declaratory judgment of non-infringement arising under the patent laws of the United States, Title 35 of the United States Code. Carrum requests this relief because Defendants MDsave Shared Services, Inc. and MDsave, Inc. (collectively, "MDsave") claim that Carrum infringes U.S. Patent Nos. 9,123,072 (the "'072 Patent"); 11,030,665 (the "'665 Patent"); 11,244,370 (the "'370 Patent"); 11,315,160 (the "'160 Patent"); and 11,341,556 (the "'556 Patent") (collectively, the "Asserted Patents") by "offer[ing] a variety of services." MDsave's affirmative allegations of infringement of the Asserted Patents has created a justiciable controversy between Carrum and MDsave.
- 2. As a result of MDsave's communication to Carrum of its intention to pursue claims of infringement of the Asserted Patents against Carrum, Carrum is under reasonable apprehension of suit by MDsave.

PARTIES

- 3. Plaintiff Carrum is a Delaware corporation with its principal place of business located at 395 Oyster Point Boulevard, South San Francisco, California 94080.
- On information and belief, Defendant MDsave Shared Services, Inc. is a
 Delaware corporation with its principal place of business at 100 Winners Circle North, Suite 202,
 Brentwood, Tennessee 37027.
- On information and belief, Defendant MDsave, Inc. is a Delaware corporation with its principal place of business at 100 Winners Circle North, Suite 202, Brentwood,
 Tennessee 37027.



¹ See, e.g., Ex. 1 at 60.

1

2 3

4

5

6

7

8

9

11

10

12 13

15 16

14

17

18 19

20

21 22

23

24

25

26

27

28

JURISDICTIONAL STATEMENT

- 6. This action arises under the Declaratory Judgment Act, 28 U.S.C. § 2201, and under the patent laws of the United States, 35 U.S.C. §§ 1-390.
- 7. This Court has subject matter jurisdiction over this action under 28 U.S.C. §§ 1331, 1338(a), and 2201(a).
- 8. This Court has personal jurisdiction over MDsave. According to its public statements, MDsave is "co-located in Brentwood, Tenn[essee], and San Francisco, Calif[ornia]," which is in this District.² At least four MDsave employees are based in the San Francisco Bay Area, including MDsave's Chief Technology Officer, Product Management Lead, Principal Software Engineer, and a UX Designer.³ On information and belief, MDsave also maintains office space in San Francisco, California. MDsave is at home in this District and maintains continuous and systematic contacts with this District, and therefore this District has personal jurisdiction over MDsave.
- 9. In addition, this suit arises out of and relates to MDsave's contacts with the State of California and this District. MDsave's Chief Technology Officer, who is located in San Francisco, California, is a named inventor of the asserted '160 Patent. MDsave has also alleged that its web platform practices or implements each of the Asserted Patents.⁴ This MDsave web platform has a dedicated page for California, inviting prospective users to "FIND PROCEDURES IN CALIFORNIA," listing doctors located in California, and inviting California residents to "Ask your doctor to join MDsave" with a link to a flyer to provide to one's doctor.5 The MDsave web platform further purports to be governed by "Terms & Conditions" directed to California residents, providing: "If you are a resident of California, you specifically waive

² See, e.g., Ex. 2 (https://www.linkedin.com/company/MDsave/) at 1; Ex. 3 (https://www.MDsave.com/media/MDsave-rated-klas-research) at 2.

³ Ex. 4.

⁴ Ex. 1 at 10, 20, 29, 35, and 51.

⁵ Ex. 5 (https://www.MDsave.com/california).

1

4

7

14

12

15

16

17

18

19 20

21 22

23

24

25

26

27

28

California Civil Code §1542, which states "6 In addition, on information and belief, aspects of MDsave's web platform, which MDsave contends practices the Asserted Patents, were designed and developed in this District by MDsave employees.

- 10. Moreover, MDsave has purposely directed into California and this District its enforcement activities regarding the Asserted Patents and related patents. On October 22, 2015, counsel for MDsave sent a letter to Carrum at its offices in San Mateo in this District to the attention of its Chief Executive Officer, who at the time lived and worked in this District and continues to live and work in this District.⁷ The letter specifically referred to one of the Asserted Patents and "recommend[ed] that Carrum Health carefully review MDsave's issued patent and their growing portfolio with counsel to assess whether the '072 patent or the recently allowed '081 application are relevant to the online healthcare marketplace products and/or services that Carrum Health is currently offering or developing."8
- 11. On January 3, 2022, Liquidax Capital, LLC ("Liquidax") issued a press release that "it is now representing MDsave in the execution and program management of the company's patent and technology licensing program within the Direct-to-Consumer (DTC) healthcare market." The press release referred to MDsave's "portfolio of intellectual property assets that currently include nine (9) patent families and over twenty-five (25) patents and/or patents pending," and asserted that "Companies in the Direct-to-Consumer (DTC) Healthcare space may not realize that they need to obtain a patent license from MDsave." ¹⁰
- 12. On January 7, 2022, Liquidax sent a letter to Carrum's Chief Executive Officer in San Mateo, California, in which it described itself as an "intellectual property ('IP') management

¹⁰ *Id.* at 3 & 4.



⁶ Ex. 6 (https://www.mdsave.com/termsandconditions) at 16.

⁷ Ex. 7.

⁸ *Id.* at 1-2.

⁹ Ex. 8 (https://www.einnews.com/pr news/559698434/liquidax-partners-with-mdsave-toexecute-patent-licensing-program-for-direct-to-consumer-dtc-healthcare-markets) at 2.

1 | f 2 | S 3 | F 4 | S 5 | F 6 | V 7 | " 8 | a 9 | a 10 | F

11

12

13

14

15

16

17

18

firm" that "exclusively represent[s] MDsave, Inc. and its sister organization MDsave Shared Services, Inc. (together known as 'MDsave') in the administration of its business-to-business patent and technology licensing programs." The letter further referred to Carrum "products and services relating to an online marketplace in which transactions of medical services and payments are facilitated" and alleged that the "Carrum solution is overlapping in specific areas with the MDsave intellectual property portfolio." The letter attached a spreadsheet titled "MDsave Shared Services Patent Portfolio" that listed each of the Asserted Patents or the patent application that led to it. The January 7, 2022 letter asked Carrum to "review and discuss the aforementioned patents with your technical and legal staff" and "get back to us as soon as possible—ideally by January 21st, 2022."

13. On January 28, 2022, Carrum's counsel responded to Liquidax requesting that all correspondence regarding the matter be directed to counsel.¹⁵

14. On or around February 20, 2022, on behalf of MDsave, Liquidax provided to Carrum a presentation asserting the "MDsave patent portfolio covers a variety of technology concepts important to operate online healthcare services." The presentation also asserted that "Carrum Health is using MDsave's patented technology." The presentation specifically discussed the '072 Patent, asserted there was an "Implementation by MDsave," and included slides showing side-by-side claim language from the '072 Patent with "Evidence from Carrum

19

20

21

22

23

24

25

26

27

28

¹¹ Ex. 9 at 1.

¹² *Id.* at 2.

¹³ *Id.* at 3-6.

¹⁴ *Id*. at 2.

¹⁵ Ex. 10.

¹⁶ Ex. 11 at 3.

¹⁷ *Id.* at 6.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

